aTYR PHARMA INC (ATYR) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.18

From 52W high−84.10%

Volume2.08M

Market cap$16.38M

P/E (TTM)—

P/S (TTM)86.2x

Div yield—

Key dataOct 19, 2026

Open

$0.18

From 52W high

−84.10%

Volume

2.08M

Market cap

$16.38M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.5x

P/E (TTM)

—

RSI (14)

14.2

MomentumView details →

1D Return

−4.02%

YTD Return

−77.92%

SummaryUpdated Jun 1, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR) is a clinical-stage biotherapeutics company founded in 2005 and headquartered in San Diego, California. The company specializes in discovering and developing novel medicines based on immunological pathways, with a particular focus on treating rare inflammatory and fibrotic diseases. aTyr has evolved from its early research into aminoacyl-tRNA synthetases to become a focused developer of potential treatments for serious lung diseases, with its lead candidate efzofitimod currently in late-stage clinical trials for pulmonary sarcoidosis.

Ask drillr about aTYR PHARMA INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.5x

EV/Sales

−157.5x

P/S (TTM)

86.2x

P/B (TTM)

0.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−124.64%

ROA (TTM)

−87.08%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+22.50%

FCF YoY

+1.50%

Revenue CAGR 3Y

−73.65%

EPS CAGR 3Y

+6.98%

EBITDA YoY

+10.80%

MomentumView details →

1D Return

−4.02%

YTD Return

−77.92%

1Y Return

−83.05%

RSI (14)

14.2

vs 50D SMA

−56.65%

vs 200D SMA

−72.59%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

5.12x

Quick Ratio

5.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

9.41%

Beats (12Q)

7/12

Next Q EPS Est

−$0.09

Avg Surprise (4Q)

8.62%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

190000.00

Net Income (TTM)

−60.81M

Op. CF (TTM)

−54.54M

Next earningsNov 5, 2026 →

Latest newsMore news →

aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine, Inc. to further develop and test ATYR2810, a monoclonal antibody targeting the NRP2 receptor.14h ago

aTYR PHARMA INC announced publication of findings demonstrating anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry.7d ago

Similar companies

SeaStar Medical Holding CorporationICU Jasper Therapeutics, Inc.JSPR Psyence Biomedical Ltd.PBM Hoth Therapeutics, Inc.HOTH Dyadic International, Inc.DYAI NewcelX Ltd.NCEL Find similar companies →

Latest newsMore news →

aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine, Inc. to further develop and test ATYR2810, a monoclonal antibody targeting the NRP2 receptor.14h ago aTYR PHARMA INC announced publication of findings demonstrating anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry.7d ago